Cargando…

Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes

Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambadiari, Vaia, Thymis, John, Kouretas, Dimitris, Skaperda, Zoi, Tekos, Fotios, Kousathana, Foteini, Kountouri, Aikaterini, Balampanis, Konstantinos, Parissis, John, Andreadou, Ioanna, Tsoumani, Maria, Chania, Christina, Katogiannis, Konstantinos, Dimitriadis, George, Bamias, Aristotelis, Ikonomidis, Ignatios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468804/
https://www.ncbi.nlm.nih.gov/pubmed/34573011
http://dx.doi.org/10.3390/antiox10091379
_version_ 1784573766178701312
author Lambadiari, Vaia
Thymis, John
Kouretas, Dimitris
Skaperda, Zoi
Tekos, Fotios
Kousathana, Foteini
Kountouri, Aikaterini
Balampanis, Konstantinos
Parissis, John
Andreadou, Ioanna
Tsoumani, Maria
Chania, Christina
Katogiannis, Konstantinos
Dimitriadis, George
Bamias, Aristotelis
Ikonomidis, Ignatios
author_facet Lambadiari, Vaia
Thymis, John
Kouretas, Dimitris
Skaperda, Zoi
Tekos, Fotios
Kousathana, Foteini
Kountouri, Aikaterini
Balampanis, Konstantinos
Parissis, John
Andreadou, Ioanna
Tsoumani, Maria
Chania, Christina
Katogiannis, Konstantinos
Dimitriadis, George
Bamias, Aristotelis
Ikonomidis, Ignatios
author_sort Lambadiari, Vaia
collection PubMed
description Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (n = 40), liraglutide (n = 40), empagliflozin (n = 40), or their combination (GLP-1RA+SGLT-2i) (n = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (p < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (p < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (−8.76% and −9.83%) compared with insulin or SGLT2i (−0.5% and 3.22%), (p < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (−30.15% and −31.44%) compared with insulin or SGLT2i (4.72% and −3.74%), (p < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and −3.44%), (p < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (p < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier.
format Online
Article
Text
id pubmed-8468804
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84688042021-09-27 Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes Lambadiari, Vaia Thymis, John Kouretas, Dimitris Skaperda, Zoi Tekos, Fotios Kousathana, Foteini Kountouri, Aikaterini Balampanis, Konstantinos Parissis, John Andreadou, Ioanna Tsoumani, Maria Chania, Christina Katogiannis, Konstantinos Dimitriadis, George Bamias, Aristotelis Ikonomidis, Ignatios Antioxidants (Basel) Article Imbalance between oxidative stress burden and antioxidant capacity is implicated in the course of atherosclerosis among type 2 diabetic patients. We addressed the effects of insulin, glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and their combination on levels of oxidant and antioxidant biomarkers. We recruited a total of 160 type 2 diabetics, who received insulin (n = 40), liraglutide (n = 40), empagliflozin (n = 40), or their combination (GLP-1RA+SGLT-2i) (n = 40). We measured at baseline, at 4 and at 12 months of treatment: (a) Thiobarbituric Acid Reactive Substances (TBARS), (b) Malondialdehyde (MDA), (c) Reducing Power (RP), (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS) and (e) Total Antioxidant Capacity TAC). Dual treatment resulted in significant improvement of TBARS, MDA, and ABTS at four months compared with the other groups (p < 0.05 for all comparisons). At twelve months, all participants improved TBARS, MDA, and ABTS (p < 0.05). At 12 months, GLP1-RA and GLP-1RA+SGLT2-i provided a greater reduction of TBARS (−8.76% and −9.83%) compared with insulin or SGLT2i (−0.5% and 3.22%), (p < 0.05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater reduction of MDA (−30.15% and −31.44%) compared with insulin or SGLT2i (4.72% and −3.74%), (p < 0.05). SGLT2i and GLP-1RA+SGLT2-i showed increase of ABTS (12.87% and 14.13%) compared with insulin or GLP1-RA (2.44% and −3.44%), (p < 0.05). Only combined treatment resulted in increase of TAC compared with the other groups after 12 months of treatment (p < 0.05).12-month treatment with GLP1-RA and SGLT2i resulted in reduction of biomarkers responsible for oxidative modifications and increase of antioxidant biomarker, respectively. The combination treatment was superior and additive to each separate agent and also the beneficial effects appeared earlier. MDPI 2021-08-28 /pmc/articles/PMC8468804/ /pubmed/34573011 http://dx.doi.org/10.3390/antiox10091379 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lambadiari, Vaia
Thymis, John
Kouretas, Dimitris
Skaperda, Zoi
Tekos, Fotios
Kousathana, Foteini
Kountouri, Aikaterini
Balampanis, Konstantinos
Parissis, John
Andreadou, Ioanna
Tsoumani, Maria
Chania, Christina
Katogiannis, Konstantinos
Dimitriadis, George
Bamias, Aristotelis
Ikonomidis, Ignatios
Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
title Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
title_full Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
title_fullStr Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
title_full_unstemmed Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
title_short Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
title_sort effects of a 12-month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on oxidant and antioxidant biomarkers in patients with type 2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468804/
https://www.ncbi.nlm.nih.gov/pubmed/34573011
http://dx.doi.org/10.3390/antiox10091379
work_keys_str_mv AT lambadiarivaia effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT thymisjohn effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT kouretasdimitris effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT skaperdazoi effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT tekosfotios effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT kousathanafoteini effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT kountouriaikaterini effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT balampaniskonstantinos effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT parissisjohn effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT andreadouioanna effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT tsoumanimaria effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT chaniachristina effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT katogianniskonstantinos effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT dimitriadisgeorge effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT bamiasaristotelis effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes
AT ikonomidisignatios effectsofa12monthtreatmentwithglucagonlikepeptide1receptoragonistssodiumglucosecotransporter2inhibitorsandtheircombinationonoxidantandantioxidantbiomarkersinpatientswithtype2diabetes